Socioeconomic challenges in guideline-directed medical therapy (GDMT) implementation for heart failure

Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and expert in trials in critical conditions. He leads a large research group on biomarkers and biotherapies in critical conditions, named MASCOT granted by the Université de Paris Cité and Inserm. He is part of the task force that wrote the 2021 ESC/HFA Guidelines on Heart Failure and the 2023 addendum. He was PI and co-PI of several trials including STRONG-HF published in the Lancet in 2022.

Albertino Damasceno is a Full Professor at the Faculty of Medicine, Eduardo Mondlane University in Mozambique. He formerly served as Head of the Cardiology Department at Maputo Central Hospital from 1984 to 2018 and currently leads a highly productive research unit within the hospital’s Department of Medicine. His research interests focus on hypertension and salt sensitivity, heart failure, stroke, and cardiovascular epidemiology. Dr. Damasceno has contributed to several landmark international studies, including INTERHEART, INTERSTROKE, RELY, THESUS, IMPI, REMEDY, and CREOLE, serving on their steering committees. He has authored or co-authored over 250 scientific publications, amassing more than 63,989 citations, with an h-index of 63 and an i10-index of 150. He is a member of the Lancet Commission on Hypertension, the International Society of Hypertension, the South African Heart Association, and the Pan African Society of Cardiology. He has served as a trustee of the ASO and was a member of the WHO Strategic and Technical Advisory Group for Noncommunicable Diseases (STAG-NCD). He currently serves as President of the African Heart Failure Association under PASCAR.